Literature DB >> 8690775

Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals.

P N Nehete1, P C Johnson, S J Schapiro, R B Arlinghaus, K J Sastry.   

Abstract

We have investigated the proliferative response of peripheral blood mononuclear cells from individuals infected with human immunodeficiency virus type 1 (HIV-1) to synthetic peptides from the third variable loop region (V3) in the envelope protein gp120. We tested a total of 14 peptides, corresponding to 14 HIV-1 isolates belonging to four geographical locations (clades U, A, B, and D). Although differences in relative level of responses exist between individual peptides and patients, the proliferation in response to all 14 V3 peptides was significantly greater than that to unrelated control peptides. Additionally, we observed that proliferative responses of blood cells from the 10 HIV-seropositive individuals studied from the clade B region to peptides from within clades U, A, B, and D were not significantly different, indicating the cross-reactive nature of the V3-specific cell-mediated immune responses. Even though the majority of patients also exhibited antibody responses against several V3 peptides, serum samples from 50% of clade B patients exhibited antibody cross-reactivity, while proliferative responses to V3 peptides from more than one clade were observed in 80% of patients. Importantly, in two patients, decreased CD4+ cell numbers, an important surrogate marker of disease progression, significantly correlated with loss of V3 peptide-specific proliferative responses but not antibody responses. These results have important implications toward evaluating the utility of V3 peptides for designing therapeutic and/or vaccine reagents against HIV-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690775     DOI: 10.1007/bf01540958

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  37 in total

1.  A novel HIV vaccine strategy.

Authors:  K J Sastry; R B Arlinghaus
Journal:  Hematol Pathol       Date:  1990

Review 2.  Development of artificial vaccines against HIV using defined epitopes.

Authors:  J A Berzofsky
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

3.  General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.

Authors:  R A Houghten
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

4.  A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity.

Authors:  O Picard; A Achour; J Bernard; A Halbreich; B Bizzini; V Boyer; C Desgranges; J M Bertho; A Lachgar; B Polliotti
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

5.  The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group.

Authors:  C Pedersen; E Sandström; C S Petersen; G Norkrans; J Gerstoft; A Karlsson; K C Christensen; C Håkansson; P O Pehrson; J O Nielsen
Journal:  N Engl J Med       Date:  1990-06-21       Impact factor: 91.245

6.  A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS).

Authors:  H C Lane; R T Davey; S A Sherwin; H Masur; A H Rook; J F Manischewitz; G V Quinnan; P D Smith; M E Easter; A S Fauci
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

7.  T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus-infected asymptomatic subjects.

Authors:  M T Roos; F Miedema; M Koot; M Tersmette; W P Schaasberg; R A Coutinho; P T Schellekens
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

8.  Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study.

Authors:  J A Kovacs; M Baseler; R J Dewar; S Vogel; R T Davey; J Falloon; M A Polis; R E Walker; R Stevens; N P Salzman; Lane H. Clifford
Journal:  N Engl J Med       Date:  1995-03-02       Impact factor: 91.245

9.  HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.

Authors:  C A Boucher; J M Lange; F F Miedema; G J Weverling; M Koot; J W Mulder; J Goudsmit; P Kellam; B A Larder; M Tersmette
Journal:  AIDS       Date:  1992-11       Impact factor: 4.177

10.  Use of interleukin-2 in patients with acquired immunodeficiency syndrome.

Authors:  H C Lane; J P Siegel; A H Rook; H Masur; E P Gelmann; G V Quinnan; A S Fauci
Journal:  J Biol Response Mod       Date:  1984-10
View more
  2 in total

1.  Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians.

Authors:  M R Betts; J Krowka; C Santamaria; K Balsamo; F Gao; G Mulundu; C Luo; N N'Gandu; H Sheppard; B H Hahn; S Allen; J A Frelinger
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines.

Authors:  Eric A Weaver; Pramod N Nehete; Stephanie S Buchl; Julien S Senac; Donna Palmer; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.